Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

(2021) John Kuruvilla et al.   LANCET ONCOLOGY

Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies

(2020) Guillaume Fargeot et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy

(2019) Sara Mariotto et al.   LEUKEMIA & LYMPHOMA

Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease

(2019) Ann S. LaCasce   HEMATOLOGICAL ONCOLOGY

Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management

(2018) Stephen M. Ansell   AMERICAN JOURNAL OF HEMATOLOGY

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

(2018) Craig H. Moskowitz et al.   BLOOD

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas

(2017) Sally F. Barrington et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

(2017) H Miles Prince et al.   LANCET

An Update on the Role of Interim Restaging FDG-PET in Patients With Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

(2017) Craig H. Moskowitz et al.   Journal of the National Comprehensive Cancer Network

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

(2016) R. Chen et al.   BLOOD

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

(2014) A. K. Gopal et al.   BLOOD

Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy

(2014) H. Nagai   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers

(2013) A. Biggi et al.   JOURNAL OF NUCLEAR MEDICINE

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

(2011) C. H. Moskowitz et al.   BLOOD